What is NOV03?
NOV03 is an investigational, proprietary, water-free, and preservative-free eye drop based on Novaliq’s patented EyeSol technology.
The drop rapidly spreads across the ocular surface because of its low surface/interfacial tension and interacts with the lipophilic part of the tear film that prevents tear evaporation.
NOV03 also penetrates meibomian glands, where it has been reported to interact with and dissolve the altered, viscous meibum in the glands. (1)
What did the clinical trials show?
The most recent phase 3 trial showed that NOV03 met both primary endpoints of improved total corneal fluorescein staining and improved eye dryness endpoints at day 57. More results here.
What's next?
Now we wait. NDA submission can take the FDA up to 1 year to approve.